title: Evaluation of mizoribine as an immunosuppressant in subrenal capsule assay using immunocompetent mice.
abstract: We studied the application of mizoribine (MZR) to normal immunocompetent mice in subrenal capsule assay (SRCA) by means of tumor growth curve determination, histological analysis and autoradiography. At 400 mg/kg, MZR prolonged the actual tumor growth and moderately reduced the host reaction. Doses below 200 mg/kg did not effectively suppress the host reaction. The maximal weight loss of mice in the 400 mg/kg group reached 29%, but did not exceed 10% within 8 days. Hence, we applied 400 mg/kg of MZR to SRCA for up to eight days for cancer chemotherapy testing. This dose of MZR did not affect the labeling index of tumor cells compared with the control.
authors.affiliation: Department of Clinical Cancer Chemotherapy, Tohoku University, Sendai.
authors.forename: D Y
authors.initials: DY
authors.lastname: Chen
authors.forename: H
authors.initials: H
authors.lastname: Kikuchi
authors.forename: M
authors.initials: M
authors.lastname: Asamura
authors.forename: M
authors.initials: M
authors.lastname: Gamoh
authors.forename: A
authors.initials: A
authors.lastname: Wakui
mesh_terms: D000818:Animals; D001345:Autoradiography; D001835:Body Weight / Q000187:drug effects; D003520:Cyclophosphamide / Q000494:pharmacology; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008811:Mice, Inbred DBA; D012263:Ribonucleosides / Q000494:pharmacology*; D013370:Subrenal Capsule Assay
chemical_list: D007166:Immunosuppressive Agents; D012263:Ribonucleosides; C010052:mizoribine; D003520:Cyclophosphamide